Revolutionizing TNFR2 Agonism for Autoimmunity & CNS Diseases: Creation of High Potency Antibodies with Tiny Concentrations

Time: 9:30 am
day: Conference Day Two


  • The design of agonistic antibodies to surface receptors of the TNF family have been challenging to make and dose correctly in human clinical trials
  • Our group has focused on single cell surface hexagonal networks to form the tight clustering for potent intracellular signaling, such as for TNFR2 agonism instead of bridging ADCC mechanisms
  • TNFR2 agonist antibodies with high potency and validity across broad dose responses demonstrate the validity of single cell hexagonal clustering